Eidos Therapeutics Inc. (EIDX) 13D/13G Filings for BridgeBio Pharma, Inc. (BBIO)

Eidos Therapeutics Inc. 13D and 13G filings for BridgeBio Pharma, Inc.:

  • Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
  • Shares have been adjusted for stock splits.
Time period
Reported
DateTime		Transaction
Date		TypeCompany
Symbol		Filed By
Symbol		Shares Owned
% Owned		Shares Vs. Prev ReportView
2021-01-26
4:23 pm
Sale		2021-01-2613DBridgeBio Pharma, Inc.
BBIO		Eidos Therapeutics Inc.
EIDX		0
0.000%		-44,651,896decrease
(Position Closed)		Filing
2020-10-15
4:17 pm
Purchase		2020-10-0513DBridgeBio Pharma, Inc.
BBIO		Eidos Therapeutics Inc.
EIDX		44,651,896
36.400%		44,651,896increase
(New Position)		Filing